Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: Insights from study of coronary atheroma by intravascular ultrasound: Effect of rosuvastatin versus atorvastatin

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 11, 2014, Pages 2465-2472

  Puri, Rishi ^a   Nissen, Steven E ^a   Shao, Mingyuan ^a   Ballantyne, Christie M ^b   Barter, Philip J ^c   Chapman, M John ^d   Erbel, Raimund ^e   Libby, Peter ^f   Raichlen, Joel S ^g   Uno, Kiyoko ^h   Kataoka, Yu ^h   Nicholls, Stephen J ^b,h  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ASTRAZENECA   (United Kingdom)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Acute coronary syndrome; Atherosclerosis; Statins, HMG CoA

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; APOLIPOPROTEIN A; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTENSIVE CARE; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; SMOKING; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DOSE RESPONSE; ECHOGRAPHY; FOLLOW UP; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84911932109     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303932     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Fox K A, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177-1189.
3. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
4. Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, Kellett MA, Stuckey T, Fahy M, Mehran R, Stone GW. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention. 2013;8:1134-1142.
5. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronar y arterial stenosis at prior angiography. Am J Cardiol. 1992;69:729-732.
6. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, M arso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235.
7. Rioufol G, Finet G, Ginon I, André-Fouë t X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-808.
8. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg. 2008;47:296-302.
9. Iwakiri T, Yano Y, Sato Y, Hatakeyama K, Marutsuka K, Fujimoto S, Kitamura K, Kario K, Asada Y. Usefulness of carotid intima-media thickness measu rement as an indicator of generalized atherosclerosis: findings from autopsy analysis. Atherosclerosis. 2012;225:359-362.
10. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 A CC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889-934.
11. Reiner Z,Catapano AL,De Backer G,et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32:1769-1818.
12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
13. Hulten E, Jackson JL, Douglas K, Geor ge S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a metaanalysis of randomized controlled trials. Arch Intern Med. 2006;166: 1814-1821.
14. Josan K, Majumda r SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178:576-584.
15. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Bra unwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54:2358-2362.
16. Mills EJ, O'Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Inte nsive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of 40 000 patients. Eur Heart J. 2011;32:1409-1415.
17. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012;109:1239-1246.
18. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010;160:1130- 6, 1136.e1.
19. Melloni C, Shah BR, Ou FS, Roe MT, Smith SC Jr, Pollack CV Jr, Ohman M, Gibler WB, Peterson ED, Alexander KP. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd Su sTAINed Over Time (MAINTAIN) registry. Am Heart J. 2010;160:1121- 9, 1129.e1.
20. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Lesl ie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718
21. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405-1410.
22. Briel M, Schwartz GG, Thompson PL, de Lemos JA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046-2056.
23. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, N issen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-2087.
24. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55:2399-2407.
25. Tian J, Gu X, Sun Y, Ban X, Xiao Y, Hu S, Yu B. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disorders. 2012;12:70.
26. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013.
27. Nissen SE, Tsunoda T , Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
28. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early s tatin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulati on. 2004;110:1061-1068.
29. Rodé s-Cabau J, Tardif JC, Cossette M, Bertrand OF, Ibrahim R, Larose E, Grégoire J, L'allier PL, Guertin MC. Acute effects of statin therapy on coronary atherosc lerosis following an acute coronary syndrome. Am J Cardiol. 2009;104:750-757.
30. Eshtehardi P, McDaniel MC, Dhawan SS, Binongo JN, Krishnan SK, Golub L, Corban MT, Raggi P, Quyyum i AA, Samady H. Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function. J Invasive Cardiol. 2012;24:522-529.
31. K ini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, Fuster V, Narula J, Sharma SK, Moreno PR. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21-29.
32. Puri R,Wolski K,Uno K,Kataoka Y,King KL,Crowe TD,Kapadia SR,Tuzcu EM,Nissen SE,Nicholls SJ. Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. JACC. Cardiovasc Interv. 2013;6:29-35.
33. . Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Coronary atheroma volume and cardiovascular events during maximally inten sive statin therapy. Eur Heart J. 2013;34:3182-3190.
34. Shiu JR, Pearson GJ, Charrois TL, Gyenes G, Koshman SL. Frequency of intensive statin therapy in patients with acute coronary syndrome admitted t o a tertiary care center. Am J Cardiol. 2012;109:1-5.
35. Maggioni AP, Rossi E, Cinconze E, De Rosa M. Use and misuse of statins after acs: Analysis of a prescription database of a community set ting of 2,042,968 subjects. Eur J Prev Cardiol. 2013;9:1109-16
36. Andrikopoulos G, Tzeis S, Nikas N, Richter D, et al. Short-term outcome and attainment of secondary prevention goals in pat ients with acute coronary syndrome-results from the countrywide TARGET study. Int J Cardiol. 2013;168:922-927.
37. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, et al. AHA/ACCF secondary pre vention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432-2446.
38. . Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation. 2013;127:769-781.
39. Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-t erm effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014;15:380-388.
40. Thim T, Hagensen MK, Wallace-Brad ley D, Granada JF, Kaluza GL, Drouet L, Paaske WP, Bø tker HE, Falk E. Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease. Circ Cardiovasc Imaging. 2 010;3:384-391.